Peptinnovate Ltd Alternatives & Competitors

12 companies similar to Peptinnovate Ltd

InflaRx

Controlling Inflammation - developing drugs to treat life threatening and chronic inflamma...

46 Post-IPO Equity $250.20M

Jena, Germany

Health Care Health and Wellness +1

Resolvyx Pharmaceuticals

Crafting the future of medicine by harnessing the body’s natural ability to resolve inflam...

11-50 Venture round $45.70M

Biotechnology Health and Wellness +1

Alvine Pharmaceuticals

Pioneering solutions for autoimmune and gastrointestinal health with a promising treatment...

1 Debt Financing $68.01M

Biotechnology Health and Wellness +1

Apellis Pharmaceuticals

Global biopharma company leveraging courageous science, creativity, and compassion to deli...

769 Post-IPO Debt $643.53M

Waltham, United States

Biotechnology Health Care +2

Track all Peptinnovate Ltd competitors

Get real-time alerts when any of these companies raise funding, hire, or show growth signals.

See how it works

Crinetics Pharmaceuticals

Driving the next generation of endocrinology care. #acromegaly #crinetics #CarcinoidSyndr...

612 IPO $1.48B

San Diego, United States

Biotechnology Health Care +2

Alphyn Biologics, Inc.

Alphyn develops first-in-class, multi-target therapeutics for atopic dermatitis & other se...

4 Venture round $11.83M

United States

Health Care Health and Wellness +2

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT)

Delivering meaningful innovation in medical dermatology.

448 Post-IPO Equity $833.50M

Westlake Village, United...

Biopharma Biotechnology +3

Microbion Corporation

Developing a disruptive new class of therapeutic drugs for the treatment of rare, chronic,...

16 Venture round

Bozeman, United States

Biotechnology Health Care +2

KYAN Therapeutics

Advanced AI for Faster, Safer Drug Development and Optimized Therapies

2-10 Seed $5.00M

AI Biopharma +6

Allena Pharmaceuticals, Inc.

Developing Therapeutics for Patients with Rare and Severe Metabolic and Kidney Disorders

13 Post-IPO Equity $198.80M

Newton, United States

Biotechnology Health and Wellness +1

SolAeroMed Inc.

3 Seed $101.04K

Biotechnology Health and Wellness +1

NeuroTherapia, Inc.

Treating Neuroinflammation... Treating Disease™

9 Grant $11.50M

United States

Health Care Health and Wellness +1

About Peptinnovate Ltd

Peptinnovate Ltd, founded in 2011, is a pharmaceutical company that focuses on researching and developing innovative new therapies to address immuno-inflammatory diseases such as asthma, atopic dermatitis, and inflammatory bowel disease. These diseases are characterized by chronic inflammation, which, if left uncontrol...

Business keywords

Immunology, Inflammatory Diseases, Drug Development, Therapeutics, Clinical Research, Safety, Efficacy, Chronic Inflammation, Therapy Development, Disease Modification, Remission, Clinical Trials, Pharmaceuticals, Healthcare Innovation

Frequently Asked Questions

Companies similar to Peptinnovate Ltd include InflaRx, Resolvyx Pharmaceuticals, Alvine Pharmaceuticals, Apellis Pharmaceuticals, Crinetics Pharmaceuticals. They work in Health and Wellness and Pharmaceutical and share Peptinnovate Ltd's focus on drug development, therapeutics and clinical trials.

Bounce Watch lists 12 companies that share Peptinnovate Ltd's industries and are closest to it in business tags, services, target customers, business model and size.

Don't just read about them. Follow them.

BounceWatch watches Peptinnovate Ltd and millions of other companies. When one raises money, hires quickly or changes its product, we tell you the same day.

See how it works

Explore Related

Peptinnovate Ltd Profile InflaRx Alternatives Resolvyx Pharmaceuticals Alternatives Apellis Pharmaceuticals Alternatives All Companies All Signals Trend Reports

Compiled from the BounceWatch company index. We last looked at Peptinnovate Ltd on 12 Sep 2024. The 12 companies listed here were last checked between 25 Jul 2024 and 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.